{
  "pmcid": "10527595",
  "sha256": "25dd2800de01043f06b9e5e14e74162775559bc09c12026341c10422006eb4b5",
  "timestamp_utc": "2025-11-09T23:07:27.488971+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.05756772673734,
    "reading_ease": 29.44938260698865,
    "word_count": 283
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Immediate Lymphatic Reconstruction for Reducing Breast Cancer-Related Lymphedema: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "women undergoing ALND for breast cancer were randomised 1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "women undergoing ALND for breast cancer"
      },
      "Intervention": {
        "score": 2,
        "evidence": "ILR involved lymphatic anastomosis to a regional vein using microsurgical techniques, while the control group had cut lymphatics ligated"
      },
      "Objective": {
        "score": 1,
        "evidence": "investigates the efficacy of immediate lymphatic reconstruction (ILR) in decreasing the incidence of breast cancer-related lymphedema (BCRL)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of BCRL, defined as â‰¥10% relative volume change (RVC) from baseline in the affected extremity at 12, 18, or 24 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 144 patients were randomised, with 72 in each group"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Preliminary analysis includes 99 patients with 12-month follow-up, 70 with 18-month follow-up, and 40 with 24-month follow-up"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The cumulative incidence of BCRL was 9.5% in the ILR group and 32% in the control group (p=0.014)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Registration Number]"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of Funding]"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}